Rallybio Corporation Ends RLYB212 Program, Shares Plummet 41.2%
AinvestWednesday, Apr 9, 2025 12:08 pm ET
1min read Rallybio Corporation announced the termination of its pregnancy-related rare disease program RLYB212 due to pharmacokinetic data showing inadequate target concentrations for efficacy. The company is now focused on developing its lead candidate RLYB116 for treating complement-driven diseases. Rallybio's shares plummeted 41.2% following the announcement.
View Source
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
